Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow
Design Therapeutics, Inc. recently presented data from the RESTORE-FA trial of their drug DT-216P2, aimed at treating Friedreich Ataxia. The presentation included a slide deck detailing the findings of the trial. This event highlights the company's ongoing research and development efforts in addressing this rare genetic disorder.
- ▪Design Therapeutics, Inc. discussed data from the RESTORE-FA trial of DT-216P2.
- ▪The trial focuses on treating Friedreich Ataxia, a rare genetic disorder.
- ▪The presentation included a detailed slide deck outlining the trial's findings.
Seeking Alpha files mainly under finance. We currently carry 6,426 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906509-design-therapeutics-inc-dsgn-discusses-data-from-restore-fa-trial-of-dtminus-216p2-for"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
